Work

Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor–Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance)

Year: 2020

Type: article

Abstract: To investigate whether anti–vascular endothelial growth factor therapy with bevacizumab prolongs progression-free survival (PFS) when added to first-line letrozole as treatment of hormone receptor–positive metastatic breast cancer (MBC).

Source: UNC Libraries

DOI: 10.17615/9rf0-wj19

Authors: Schneider, Bryan P., Barry, William T., Hudis, Clifford A., Cirrincione, Constance T., Dickler, Maura N., Ellis, Matthew J., Lake, Diana E., Winer, Eric P., Carey, Lisa A., Moynahan, Mary Ellen, Hahn, Olwen, Hurria, Arti, Tripathy, Debasish, Innocenti, Federico, Rugo, Hope S.

Institution: University of North Carolina at Chapel Hill

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Eli Lilly and Company, Pfizer, GlaxoSmithKline, Celgene, Mylan, MacroGenics, Eisai, Genentech

OpenAlex ID: W4299919900

FWCI:

Cites:

Cited by:

Related to: 10